Where are we with the management of hypertension? From science to clinical practice

Journal of Clinical Hypertension

Volumn 11, Issue 2, 2009, Pages 66-73

  Farsang, Csaba ^a   Naditch Brule, Lisa ^b   Avogaro, Angelo ^c   Östergren, Jan ^d   Verdecchia, Paolo ^e   Maggioni, Aldo ^f   van de Borne, Philippe ^g   Lins, Robert ^h   Roca Cusachs, Alexandre ⁱ  

^a Szent Imre Hospital   (Hungary)

^b SANOFI   (France)

^c UNIVERSITY OF PADOVA   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^f ANMCO RESEARCH CENTER   (Italy)

^g ERASME HOSPITAL   (Belgium)

^h UNIVERSITY OF ANTWERP   (Belgium)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; GLICLAZIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ABDOMINAL OBESITY; AGE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FAMILY HISTORY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MEDICAL DECISION MAKING; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; COMORBIDITY; DIABETES MELLITUS; DIET, FAT-RESTRICTED; DIET, SODIUM-RESTRICTED; DISEASE PROGRESSION; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 60549114372     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00066.x     Document Type: Review

References (41)

1. Alderman MA, Ogihara T. Global challenge for overcoming high blood pressure: Fukuoka Statement. J Hypertens. 2007;25:727.
2. Ezzati M, Lopez AD, Rodgers A, et al; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360.
3. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
4. Kjeldsen SE, Naditch-Brule L, Perlini S, et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: The Global Cardiometabolic Profile in Patients with hypertension disease survey. J Hypertens. 2008;26:2064-2070.
5. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: A systematic review. J Hypertens. 2004;22:11-19.
6. Burke TA, Sturkenboom MC, Lu SE, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24:1193-1200.
7. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart. 2000;88:203-206.
8. Mancia G, de Backer G, Dominiczak A, et al; The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-1187.
9. Zanchetti A, Cifkova R, Fagard R, et al; for the ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens. 2003;21:1011-1053.
10. Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: Systematic review of randomised controlled trials. BMJ. 2007;334:786.
11. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines subcommittee. J Hypertens. 1999;17:151-183.
12. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113:2263-2272.
13. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
14. Nesbitt SD, Julius S, Leonard D, et al. Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY study. Am J Hypertens. 2005;17:980-985.
15. de Simone G, Olsen MH, Watchell K, et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: The life study. J Hum Hypertens. 2007;21:625-632.
16. Deen D. Metabolic syndrome: Time for action. Am Fam Physician. 2004;69:2875-2882.
17. Torpy JM, Lynn C, Glass RM. The metabolic syndrome. JAMA. 2006;295:850.
18. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type-2 diabetes mellitus. N Engl J Med. 2000;342:905-912.
19. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167:141-147.
20. Dahlöf B, Sever PS, Poulter NS, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicenter randomised controlled trial. Lancet. 2005;366:895-906.
21. Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:869-871.
22. Sever P, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial -Lipid Lowering Arm (ASCOT-LLA): A multicenter randomised controlled trial. Lancet. 2003;361:1149-1158.
23. Sever P, Poulter N, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type-2 diabetes. Diabetes Care. 2005;28:1151-1157.
24. Sever P, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27:2982-2988.
25. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type-2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-840.
26. Beckett NS, Peters R, Fletcher AE, et al; for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1-12.
27. Jamerson KA, on behalf of the ACCOMPLISH investigators. Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension. Paper presented at: American College of Cardiology Scientific Sessions; March 31, 2008; Chicago, IL.
28. Weder AB. The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A comparison of first-line combination therapies. Expert Opin Pharmacother. 2005;6:275-278.
29. Mayet J, Stanton AV, Sinclair AM, et al. The effects of antihypertensive therapy on carotid vascular structure in man. Cardiovasc Res. 1995;30:147-152.
30. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A meta-analysis. Am J Hypertens. 2003;16:895-899.
31. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
32. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-1581.
33. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet. 2007;369:201-207.
34. Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: A meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004;17:817-822.
35. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:368-392.
36. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153.
37. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes. Results of the HOPE study extension. Circulation. 2005;112:1339-1346.
38. Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trial. Hypertens Res. 2005;28:385-407.
39. The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
40. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
41. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke and transient ischemic attack. Lancet. 2001;358:1033-1041.